Drug
Information


   


      











 

Pharmacokinetics


 

Mianserin is readily absorbed from the gastrointestinal tract, but its
bioavailability is reduced by extensive first-pass metabolism in the
liver.

Paths of metabolism of mianserin include aromatic hydroxylation,
N-oxidation, and N-demethylation. Desmethylmianserin and
8-hydroxymianserin are pharmacologically active.

Mianserin is
excreted in the urine, almost entirely as its metabolites, either free
or in conjugated form; some is also found in the faeces.

Mianserin is widely distributed throughout the body and is extensively
bound to plasma proteins. It has been found to have a biphasic plasma
half-life with the duration of the terminal phase ranging from about 6
to 40 hours. Mianserin crosses the blood-brain barrier and the placenta.
It is distributed into breast milk.

 TOP

        

Indication
& Dosage


 


Oral

MILD DEPRESSION: 30mg daily at bed time increased according to responsse
upto 60-90mg daily. Some cases may need upto 150mg daily.


 

Action

 


Does not inhibit reuptake of noradrenalin (NA) in vivo. But it acts
as an atnagonist at alpha1 and alpha2 receptors. The inhibition of
alpha2 receptors increases NA release. Mianeserin also antagonises 5HT2
and 5HT1C receptors. Less antimuscarinic action than tricyclic
antidepressants. No significant cardiovascular effects.

 TOP

   

Interactions

  

It is recommended that mianserin should not be given to patients
receiving MAOIs or for at least 14 days after their discontinuation. At
least one week should elapse between withdrawing mianserin and starting
any drug liable to provoke a serious reaction (e.g. phenelzine). Unlike
the tricyclics, mianserin does not diminish the effects of the
antihypertensives guanethidine, hydralazine, propranolol, clonidine, or
bethanidine. However, it is still recommended that blood pressure be
monitored when mianserin is prescribed with antihypertensive therapy.
Plasma-phenytoin concentrations should be monitored carefully in
patients treated concurrently with mianserin; phenytoin has been
reported to reduce concentrations of mianserin. There may be
potentiation of effects when mianserin is given concomitantly with CNS
depressants such as alcohol, anxiolytics, or antipsychotics.

 TOP

    

Adverse
Effect & Precaution




Hypersensitivity reaction, nausea, drwosiness, jaundice, may precipitate
seizures, blood dyscrasias, lethargy, tremors.



Precaution: Diabetes, renal cardiac or hepatic impairment. Driving and
operating machinery. epilepsy, children. Narrow angle glaucoma, laundice,
prostate hypertrophy.

Pregnancy: Safety not established.

Breast Feeding: Use with caution.

Man: May be give in reduced dose.

 TOP

   

Brand
available in market


 



















DEPNON

Infar

TAB

10mg

10

25.50

TAB

30mg

10

65.50

MAINDEP

Mejda

TAB

10mg

10

14.33

TAB

20mg

10

27.65

SERIDAC

Alidac

TAB

10mg

10

17.20

TAB

30mg

10

45.70

TETRADEP

Torrent

TAB

10mg

10

26.90

TAB

20mg

10

49.90

TAB

30mg

10

59.90




TOP




 



 








 

 

 

   
Drug Information
   

      

 
Pharmacokinetics

 
Mianserin is readily absorbed from the gastrointestinal tract, but its bioavailability is reduced by extensive first-pass metabolism in the liver.
Paths of metabolism of mianserin include aromatic hydroxylation, N-oxidation, and N-demethylation. Desmethylmianserin and 8-hydroxymianserin are pharmacologically active.
Mianserin is excreted in the urine, almost entirely as its metabolites, either free or in conjugated form; some is also found in the faeces.
Mianserin is widely distributed throughout the body and is extensively bound to plasma proteins. It has been found to have a biphasic plasma half-life with the duration of the terminal phase ranging from about 6 to 40 hours. Mianserin crosses the blood-brain barrier and the placenta. It is distributed into breast milk.

 TOP
        

Indication & Dosage
 

Oral
MILD DEPRESSION: 30mg daily at bed time increased according to responsse upto 60-90mg daily. Some cases may need upto 150mg daily.

 

Action
 

Does not inhibit reuptake of noradrenalin (NA) in vivo. But it acts as an atnagonist at alpha1 and alpha2 receptors. The inhibition of alpha2 receptors increases NA release. Mianeserin also antagonises 5HT2 and 5HT1C receptors. Less antimuscarinic action than tricyclic antidepressants. No significant cardiovascular effects.

 TOP
   

Interactions
  
It is recommended that mianserin should not be given to patients receiving MAOIs or for at least 14 days after their discontinuation. At least one week should elapse between withdrawing mianserin and starting any drug liable to provoke a serious reaction (e.g. phenelzine). Unlike the tricyclics, mianserin does not diminish the effects of the antihypertensives guanethidine, hydralazine, propranolol, clonidine, or bethanidine. However, it is still recommended that blood pressure be monitored when mianserin is prescribed with antihypertensive therapy. Plasma-phenytoin concentrations should be monitored carefully in patients treated concurrently with mianserin; phenytoin has been reported to reduce concentrations of mianserin. There may be potentiation of effects when mianserin is given concomitantly with CNS depressants such as alcohol, anxiolytics, or antipsychotics.

 TOP
    

Adverse Effect & Precaution

Hypersensitivity reaction, nausea, drwosiness, jaundice, may precipitate seizures, blood dyscrasias, lethargy, tremors.

Precaution: Diabetes, renal cardiac or hepatic impairment. Driving and operating machinery. epilepsy, children. Narrow angle glaucoma, laundice, prostate hypertrophy.
Pregnancy: Safety not established.
Breast Feeding: Use with caution.
Man: May be give in reduced dose.

 TOP
   

DEPNON

Infar

TAB

10mg

10

25.50

TAB

30mg

10

65.50

MAINDEP

Mejda

TAB

10mg

10

14.33

TAB

20mg

10

27.65

SERIDAC

Alidac

TAB

10mg

10

17.20

TAB

30mg

10

45.70

TETRADEP

Torrent

TAB

10mg

10

26.90

TAB

20mg

10

49.90

TAB

30mg

10

59.90

TOP
 
 

 

By |2022-07-20T16:44:59+00:00July 20, 2022|Uncategorized|Comments Off on Mianserin

About the Author: